CN105030844A - 硒和益生菌的组合物及用途 - Google Patents
硒和益生菌的组合物及用途 Download PDFInfo
- Publication number
- CN105030844A CN105030844A CN201510410100.6A CN201510410100A CN105030844A CN 105030844 A CN105030844 A CN 105030844A CN 201510410100 A CN201510410100 A CN 201510410100A CN 105030844 A CN105030844 A CN 105030844A
- Authority
- CN
- China
- Prior art keywords
- selenium
- probiotics
- compositions
- diabetes
- probiotic bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011669 selenium Substances 0.000 title claims abstract description 24
- 229910052711 selenium Inorganic materials 0.000 title claims abstract description 23
- 239000006041 probiotic Substances 0.000 title claims abstract description 21
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 21
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 10
- 230000000529 probiotic effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims description 4
- 239000013589 supplement Substances 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000000378 dietary effect Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 235000020880 diabetic diet Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract description 2
- 235000015872 dietary supplement Nutrition 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 2
- 241000186012 Bifidobacterium breve Species 0.000 abstract 1
- 230000001276 controlling effect Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000005802 health problem Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 244000005706 microflora Species 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 16
- 239000008103 glucose Substances 0.000 description 16
- 229940091258 selenium supplement Drugs 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 9
- 235000001727 glucose Nutrition 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 229940039696 lactobacillus Drugs 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- -1 lipid peroxide Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001379 nervous effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明硒和益生菌的组合物及用途，含有硒0.5-1.0mg/g，益生菌总数不低于1.0×108/g，所述的益生菌由30％的两岐双岐杆菌、30％的短双岐杆菌和40％的罗伊氏乳杆菌组成，该组合物可用于制备糖尿病药物以及糖尿病人的膳食补充剂，本发明基于清除体内自由基、保护β细胞和调整肠胃道菌群及预防并发症方面进行组合，为糖尿病患者及高风险人群提高一种预防和控制健康营养品或药物。
Description
[技术领域]
本发明涉及硒和益生菌的组合物。
[背景技术]
2013年中华医学会糖尿病学分会公布糖尿病流行病学调查结果我国30岁以上人群糖尿病患病率达11.6％，估计全国有1.39亿糖尿病患者。成为世界第一糖尿病大国。
糖尿病生活方式干预主要是通过适当饮食和锻炼来降低体重(大于6公斤或体重的7-8.5％)和控制血糖。前期糖尿病人群如果没能生活方式干预控制进程，将成为糖尿病患者。美国全部糖尿病患者中,16％还可通过生活方式干预控制病情,另外86％就必须在生活方式干预的基础上采用医学治疗。
糖尿病尿病并发症是糖尿病的主要危害所在。高血糖状态对多种器官/系统有重要影响,其中对微循环的影响尤为显著，微循环并发症(糖尿病眼病、肾病、CHD、周围神经病变如足溃疡等)多是最早发生的糖尿病并发症,甚至常常是患者第一次就医的原因，患者此前的糖尿病病程可能已长达5年或者更长，只是由于无症状而没有发现。
与此同时，科学研究发现：
研究表明糖尿病的发生和发展与宿主肠道菌群有着一定的联系。糖尿病是一种代谢紊乱的疾病，某些益生菌的缺少可能与糖尿病直接相关。
日本科学家研究发现乳酸菌降血糖的作用明显：1、在实验中，研究人员让一组患糖尿病的实验鼠喝含某种乳酸菌的水，另一组患病实验鼠喝不含这种乳酸菌的水。两周后进行比较发现，前者血糖值上升幅度只有后者的一半。2、研究人员研究实验鼠的肠神经作用时发现，当乳酸菌到达肠道后，引发机体兴奋的交感神经功能受到了抑制，而起“刹车”作用的副交感神经活跃起来，肠神经兴奋时分泌的使血糖值上升的高血糖素减少，抑制了血糖值异常上升。此外研究人员还发现，这种乳酸菌通过调节肠神经还具有降血压效果。3、不同的菌株表现的降血糖的能力不一样。但是降血压的乳酸菌大多能产生一种或几种短肽的物质(如三肽,VPP和LPP等)。4、色氨酸不正常代谢后会产生黄尿酸，黄尿酸会影响胰脏功能。嗜酸乳杆菌和双歧杆菌在结肠合成VB6，促进镁离子的吸收，有助色氨酸正常代谢，促使胰腺正常分泌胰岛素。从而有助血糖恢复正常。
有资料表明，2型糖尿病病人人体内存在自由基的升高，其抗氧化酶活性，尤其谷胱甘肽过氧化物酶(GSH-Px)活性降低，脂质过氧化物(Lpo)水平增高，而补硒可改善上述状态，缓解糖尿病病情。另有报道，2型糖尿病患者体内有硒代谢紊乱，并且抗氧化酶活性降低，提示硒与糖尿病之间具有高度相关性。胰岛是氧化损害的敏感组织之一，其原因有三：1所有组织中胰岛内超氧化物歧化酶(SOD)含量是最低的，说明其抗自由基损伤系统存在先天的薄弱环节，2胰岛内分泌细胞含大量的内质网，富含多聚不饱和脂肪酸的内质网膜，在低硒状态下易成为自由基攻击的主要目标。3内质网是合成多肽类激素场所，如果GSH-Px活性降低使内质网中的自由基排除受阻，自由基即可在原位直接损害内质网膜结构。硒是GSH-Px的活性中心物质，在糖代谢的磷酸戊糖途径中，恢复糖尿病患者肝组织中的GSH-Px活性，有利于NADPH的合成，保护肝功能，从而维护肝在糖代谢中重要作用。另一方面，由于GSH-Px能分解过氧化物，减少自由基产生，故能保护胰岛素A\B肽键间二硫键免受氧化破坏，从而表现出降血糖作用：同时由于阻止脂质过氧化的连锁反应，保护生物膜结构和生物化学的完整性，改善膜的生理状态。
[发明内容]
本发明的目的在于利用硒和益生菌的上述特性制备关于糖尿病预防和控制的药物和膳食补充剂。
为了实现上述目的一种硒和益生菌的组合物，含有硒0.5-1.0mg/g，益生菌总数不低于1.0×108/g，所述的益生菌由30％的两岐双岐杆菌、30％的短双岐杆菌和40％的罗伊氏乳杆菌组成。
进一步的，还具有如下优化配方：
所述的组合物中包含膳食纤维素。
所述的组合物中包含赋形剂。
本发明还涉及上述组合物在制备糖尿病药物中应用。
所述的药物为片剂、散剂、冲服剂、胶囊剂或液态剂。
本发明还涉及上述组合物在制备糖尿病膳食补充剂中的应用。
所述的补充剂为经口施用制剂、食物产品、饮料或营养品。
本发明基于清除体内自由基、保护β细胞和调整肠胃道菌群及预防并发症方面进行组合，为糖尿病患者及高风险人群提高一种预防和控制健康营养品或药物。
[附图说明]
图1为不同组小鼠的空腹血糖值；
图2为不同组小鼠的随机血糖值；
图3为不同组小鼠的餐后血糖值；
图4为不同组小鼠的OGTT结果。
[具体实施方式]
以下，结合实施例和附图对于本发明做进一步说明，实施例和附图仅用于解释说明而不用于限定本发明的保护范围。
实施例1
胶囊剂：以1000g重量份，取膳食纤维素(市售大豆纤维素)900g，粉状富硒益生菌(含两岐双岐杆菌30％、短双岐杆菌30％、罗伊氏乳杆菌40％)约100g，天然硒作为益生菌发酵水源和硒浓度调节剂。其中含富硒益生菌总数不低于1.0×108/g，硒总含量(以Se计)0.5-1.0mg/g。每粒300mg。
当然在其中还能够适当加入赋形剂。
选取雌性8周龄II型糖尿病KKAy小鼠模型20只，适应性喂养7天后，确认KKAy小鼠肥胖后，随机分为几组。
各组动物饲养在SPF(无特异病原微生物)环境下(室温为20-26℃，湿度40-70％，14/10小时的昼夜循环)自由饮食饮水。每天采用本发明的提取组合物灌胃，连续一个月。
每周称量动物体重、空腹血糖(禁食不禁水6h后，割尾取血，快速血糖仪测定)/糖耐量实验(OGTT)(禁食6h后，给予2g/kg葡萄糖灌胃)；分析天平称取肝脏重量计算脏体比。
采用T检验进行数据分析，p<0.05，为具有显著性。
血糖(空腹血糖/随机血糖/餐后2小时血糖/糖耐量实验)
高脂饲料喂养诱导易患二型糖尿病kkay小鼠的血糖大幅度升高，如图1、2和3所示，灌胃本发明的提取组合物后，可以显著降低kkay小鼠的血糖(空腹血糖，随机血糖，餐后血糖)。糖耐量受损是II型糖尿病的前期必然阶段，图4显示高脂诱导的kkay小鼠糖耐量受损，调节血糖的能力降低，指示胰岛素抵抗，而给予各配方后的kkay小鼠糖耐量受损减轻。
Claims (7)
1.一种硒和益生菌的组合物，其特征在于含有硒0.5-1.0mg/g，益生菌总数不低于1.0×108/g，所述的益生菌由30％的两岐双岐杆菌、30％的短双岐杆菌和40％的罗伊氏乳杆菌组成。
2.如权利要求1所述的硒和益生菌的组合物，其特征在于所述的组合物中包含膳食纤维素。
3.如权利要求1所述的硒和益生菌的组合物，其特征在于所述的组合物中包含赋形剂。
4.一种权利要求1～3任一所述组合物在制备糖尿病药物中应用。
5.如权利要求4所述的应用，其特征在于所述的药物为片剂、散剂、冲服剂、胶囊剂或液态剂。
6.一种权利要求1～3任一所述组合物在制备糖尿病膳食补充剂中的应用。
7.如权利要求6所述的应用，其特征在于所述的补充剂为经口施用制剂、食物产品、饮料或营养品。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510410100.6A CN105030844A (zh) | 2015-07-13 | 2015-07-13 | 硒和益生菌的组合物及用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510410100.6A CN105030844A (zh) | 2015-07-13 | 2015-07-13 | 硒和益生菌的组合物及用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105030844A true CN105030844A (zh) | 2015-11-11 |
Family
ID=54438208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510410100.6A Pending CN105030844A (zh) | 2015-07-13 | 2015-07-13 | 硒和益生菌的组合物及用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105030844A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617096A (zh) * | 2017-02-15 | 2017-05-10 | 中国农业大学 | 一种增强胰岛功能的双歧杆菌及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014046804A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
-
2015
- 2015-07-13 CN CN201510410100.6A patent/CN105030844A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014046804A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
Non-Patent Citations (3)
| Title |
|---|
| 冯若: "《糖尿病怎么吃怎么养大全》", 31 March 2015 * |
| 杜卫佳 等: "硒的营养与生理作用研究进展", 《2012年全国养羊生产与学术研讨会议论文集》 * |
| 王锦祥: "富硒、铬益生菌的制备及其对高脂饮食ICR小鼠脂代谢的影响", 《中国优秀硕士学位论文全文数据库农业科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617096A (zh) * | 2017-02-15 | 2017-05-10 | 中国农业大学 | 一种增强胰岛功能的双歧杆菌及其应用 |
| CN106617096B (zh) * | 2017-02-15 | 2020-12-18 | 中国农业大学 | 一种增强胰岛功能的双歧杆菌及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103238897B (zh) | 一种适用于糖尿病人的复合植物固体饮料 | |
| Capcarova et al. | Effect of Lactobacillus fermentum and Enterococcus faecium strains on internal milieu, antioxidant status and body weight of broiler chickens | |
| JP4553604B2 (ja) | 一般食品、保健機能食品または健康補助食品の機能増強組成物及びその方法 | |
| Capcarova et al. | The effect of selected microbial strains on internal milieu of broiler chickens after peroral administration | |
| CN104740138A (zh) | 包含芦荟、益生菌和益生元的组合物及其用途 | |
| CN105029407A (zh) | 炎性肠病医学配方食品 | |
| MX2011000737A (es) | Probioticos para aumentar la secrecion de iga en infantes nacidos a traves de operacion cesarea. | |
| Putta et al. | Probiotics: supplements, food, pharmaceutical industry | |
| CN110623182A (zh) | 一种用于治疗高尿酸及痛风的益生菌植物固体饮料 | |
| JP2011116666A (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤及びその製造方法 | |
| US9895400B2 (en) | Composition and use of Lactobacillus reuteri GMNL-263 in decreasing blood lipid levels | |
| CN113163832A (zh) | 用于增强胰腺成熟和胰岛素生物合成的婴儿营养组合物 | |
| CN110754656A (zh) | 一种淋巴肿瘤功能专用型临床营养配方及其制备方法 | |
| EP3677273A1 (en) | Application of bacteroides cellulosityticus in preparing a preparation for preventing and/or treating lipid metabolism related diseases | |
| Campaniello et al. | A narrative review on the use of probiotics in several diseases. Evidence and perspectives | |
| CN104839678A (zh) | 肾病医学配方食品 | |
| CN112385843A (zh) | 含复合益生元的均衡营养粉及其制备方法 | |
| CN105030844A (zh) | 硒和益生菌的组合物及用途 | |
| CN104839676A (zh) | 胃肠道吸收障碍医学配方食品 | |
| CN108523123A (zh) | 一种糖尿病全营养支持食品 | |
| Surolia et al. | Synbiotics: A promising approach for improving human health | |
| CN110638842A (zh) | 一种改善高血糖的益生菌组合物 | |
| CN104127594A (zh) | 应用于糖尿病预防与控制的植物提取组合物 | |
| GB2535177A (en) | Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels | |
| KR20200046959A (ko) | 당뇨병 예방용 건강기능식품 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170929 Address after: Haicang District of Xiamen City, Fujian province 361000 Weng Kok Road No. 2052 Haicang Biomedical Industry Park No. 2 floor third unit 03 Applicant after: Xiamen set biological medicine technology Co., Ltd. Address before: 450004 Henan province Zhengzhou City Road No. 11 Building No. 1 Hospital No. 14 Applicant before: Sun Zhanqiang Applicant before: Sun Yan Applicant before: Hai Kuo |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151111 |